Next Phase Newsletter

A new venture capital firm established in early 2019 by a network of hospitals, clinics, and home care services with a presence in multiple states in the USA. The firm’s first fund closed at $100M and is reserved for direct, strategic investment in early-stage companies (with approximately half of this allocation dedicated to follow-on investments). The firm’s initial investments are usually in the range of $1-3M, and it is geography agnostic and will consider all technologies across the globe.

The firm’s investments focus on these 4 verticals: digital health, medical devices, healthcare technology systems, and healthcare services. The firm will not invest in biopharmaceuticals or in vitro diagnostics, though they may consider life science tools. In terms of medical devices, the firm prefers to invest in products who have achieved FDA approval, though the firm may consider and is open to speaking with earlier stage companies with strong fit. The firm expects technologies to have a strong alignment with the hospital network, and these technologies need to be useable and easily integrated with the health system. Practically, the firm expects to have a contract (or direct line of sight to a contract) at the time of investment. Some areas of particular interest include mental and behavioral health, postpartum care, interoperability among devices and health records, cognitive support for millennials, use of voice to diagnose and monitor health conditions, etc. Overall, the firm will take high interest in technologies that help deliver care outside of the hospital.

While the firm has no specific team requirements, the firm does like to see entrepreneurs and management teams with a strong tie to the product or market. To date, the firm has only done follow-on investments as part of a syndicate, but will be open to acting as lead investor in future opportunities, most likely starting from 2020 and beyond.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A $300 million strategic corporate venture capital fund by a full-fledged oncology pharmaceutical company headquartered in Japan seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in the USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to TPC’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the firm’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional options or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

By Momo Yamamoto, Investor Research Analyst, LSN

Life Science Nation (LSN) is excited to announce our largest RESI of 2024: RESI JPM San Francisco! It takes place at the Marines’ Memorial Hotel on January 9 followed by virtual partnering on January 10-11. LSN is expecting over 500 investors and strategic partners and 500 startup companies to attend the conference.

In addition to partnering, Innovator’s Pitch Challenge (IPC) sessions, and educational workshops, we will be hosting a robust schedule of investor panels. Gathered by seasoned investors and industry experts, we are looking forward to hearing about upcoming trends, areas to avoid, valuable practical advice, and more! Please join us to listen in on the following investor panel topics:

Panel recruitment remains ongoing as we seek out speakers and their stories through early-stage investment. If you are an accredited investor in our LSN database and interested in joining any of these panels, please contact LSN research team at research@lifesciencenation.com.

By Caitlin Dolegowski, Marketing Manager, LSN

Calling all life science industry sponsor partners and media outlets: partner with us in promoting Life Science Nation (LSN)’s RESI conference series in 2024 and get valuable discounts for the members of your ecosystem! LSN is prepping for our biggest conference in the new year, RESI JPM. As we look forward to preparations for this conference during the largest life science week of the year hosted by JP Morgan in San Francisco, we are looking for sponsors and media partnerships.

LSN’s partnering conference series is the biggest in North America focusing on early-stage life science investments and strategic partnerships. At each conference event, we expect between 700-1,200 attendees to participate from more than 8 continents.

Benefits of sponsoring a RESI conference include increasing global brand and reach, sourcing, vetting, and developing key relationships with your target audience, showcasing your product and services through workshops and panels, and using our one-of-a-kind match-based partnering platform to connect with strategic partners and build relationships.

Check out our Sponsorship Brochure to meet your goals and reach your intended audience.

Media partnership isn’t just a promotional tool for publicity and customer loyalty, it can also be expected to generate goodwill and awareness at LSN’s conference series. LSN makes media sponsorship as convenient as possible. As a media sponsor, you would promote and advertise LSN partnering conferences through your communication channels, and in return, LSN offers including:

• Your logo on LSN’s Next Phase Newsletter (45,000+ readership), event websites, and program guide.
• A unique discount for your subscribers for RESI conferences.
• Our media partners receive a complimentary ticket and additional free tickets for every two registrations you provide.
• For additional exposure we offer two posts on our LinkedIn network and a banner ad featured in our newsletter during 2024.

For more information, please contact Caitlin Dolegowski, Marketing Manager, LSN

By Cameron Hurlburt, Manager of Business Development – West Coast (US), LSN

Life Science Nation (LSN) has been at the forefront of fostering invaluable connections between investors and innovators, and for the past decade, LSN has helped 400+ companies raise $5B+ through 45+ RESI conferences and LSN products. LSN understands that securing the right investor is paramount to your company’s success. That is why we offer a key step to the process of successful fundraising, the Investor and Licensing Partner Database.

The Investor and Licensing Partner Database subscription provides details of 3,000+ investment firms across 10,000+ contacts in the early-stage life sciences industry. It is a comprehensive collection of insights and connections right at your fingertips. With over 80 sub-sectors and indications to search and filter from, life science CEOs can craft a precisely targeted list of investors that is perfectly aligned with their company’s partnering and fundraising goals. LSN’s Database is available in two formats, as a standalone database or integrated into Salesforce via the Salesforce App exchange as the LSN Global Partnering Campaign (GPC) app. All the information is sourced and maintained by LSN’s Investor Research Analyst team, and includes key data as follows:

Allocation Information: Discover an investor’s usual investment range, their inclination towards specific investment rounds, and whether they lead rounds or prefer co-investment.

Sectors and Subsectors of Interest: Gain clarity on the sectors they actively invest in, whether they lean towards opportunistic or specialized sectors, and if they are eyeing specific subsectors.

Company and Management Team Requirements: Understand any specific company or management team prerequisites they have before making investments.

Message From Investor: Learn how potential companies should initiate contact, including what materials to share in the initial outreach.

To explore how the LSN Investor and Licensing Partner Database can open doors to the investors and strategic partners who are the best fit for your company’s technology and stage of development, please fill out your information here. A member of the LSN Business Development team will contact you and walk you through the process to demonstrate how our platform is critical to securing the funding you need

Do not miss this opportunity to unlock the path to strategic investor connections.

Life Science Nation Business Development Team
East Coast  (USA) & International	Midwest (USA) & Canada	West Coast  (USA)	Southeast (USA) & Global Tech hubs
Greg Mannix Vice President International Business Development Book a Meeting Email Me	Antoinette Lowre Manager of Business Development Book a Meeting Email Me	Cameron Hurlburt Manager of Business Development Book a Meeting Email Me	Erika Wu Manager of BD, Global Tech Hubs Book a Meeting Email Me

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to apply to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. Each finalist company also prepares a posterboard to be showcased in the exhibit hall and competes for “RESI Cash” which attendees use to “invest” in their favorite presenters for the final prizes.

Learn more about the IPC and hear from 2023 winners. The following interviews were with companies and founders who have found value in the process and connections associated with their pitch experience with RESI:

• Thrive Interview (1^st place, RESI Boston June)
• SiVEC Biotechnologies (1^st place, RESI March)

RESI JPM is the largest conference that LSN organizes, attracting 500+ investors and 500+ early-stage startups. Participating in the IPC is a great way to boost your visibility and receive valuable feedback from relevant investor judges and strategic partners. Do not miss out on the opportunity to pitch and start fundraising in the new year on the right foot, during the life science industry’s busiest week in San Francisco!

The deadline to apply is Wednesday, November 22, but slots are filled on a first come, first served basis so we highly encourage early application submissions!

Ray Briscuso

Interview with Ray Briscuso, Executive Vice President of AdvaMedBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Dennis Ford

Dennis Ford (DF): I’m joined today by Ray Briscuso, Executive Vice President of AdvaMed and the person responsible for AdvaMed conferences and events, including The MedTech Conference taking place October 8-11 in Anaheim, CA.  If you are a medtech or digital health investor or company, you will want to listen to this interview and perhaps take advantage of this once-a-year opportunity.

Ray, for those that don’t know AdvaMed how you would describe your organization:

Ray Briscuso (RB): Thank you Dennis, it’s always a pleasure to spend time with you and I appreciate the chance to sit and talk with you today. To answer your question, AdvaMed is short for the Advanced Medical Technology Association.  We are the world’s largest trade organization representing medical device, diagnostic and digital health companies.  In all we represent over 475 manufacturers and developers including most of the leading global strategics including J&J, Medtronic, Abbott, BD, Stryker, B. Braun, Siemens Healthineers, Boston Scientific, Edwards Lifesciences, Philips, Zimmer Biomet, Smith + Nephew, Alcon, Roche Diagnostics, Danaher, Intuitive, Integra, Teleflex, Terumo, Olympus, Cardinal Health , Baxter, Hologic, GE Healthcare, Google, Amazon and Apple plus more than two hundred early-stage entrepreneurial companies.  AdvaMed advocates for patient access to safe, effective, and innovative medical technologies that save and improve lives.  We also convene the industry, build consensus, and promote the growth of the medtech industry.

DF: Ray, you’ve been with AdvaMed for 15+ years, and you’ve spent more than 30 in the life science space, for an aspiring CEO or medtech inventor, do you have any words of wisdom on how they can take those necessary big leaps that are required to succeed in this industry?

RB: Happy to try – for starters, be a part of the community, attend industry gatherings and get to know your peers and network and build relationships throughout the entire ecosystem. Get to know investors, payers, regulators, service providers, and of course peers.  If you live in Massachusetts, join MassMEDIC, if you live in Minnesota join Medical Alley – nearly every cluster and/or state and region has an organization that gathers your peers and enablers, and you should join your local peers and consider joining AdvaMed.  Learn from your peers, network, and share.  Go to key industry events and build relationships. You and LSN do a terrific job with your RESI series, and I am very proud of The MedTech Conference and the events produced by AdvaMed. The MedTech Conference annually gathers 3000+ attendees including some 500 medtech CEOs, over 250 investors and key decision makers from every sector and all parts of the ecosystem including regulators, payers, contract designers and manufacturers.

DF: The MedTech Conference promotes itself as “the annual meeting of the medical technology industry.” With all the health care meetings and conferences taking place throughout the year, what makes this event special?

RB: The MedTech Conference is unique in that CEOs, heads of business development, regulatory agency heads, investors are all here and all accessible and not hidden or kept behind locked doors or private rooms.  You see them in the hall, you sit and talk to them on the conference floor, everyone is here, and everyone is accessible.  The unique feature is that The MedTech Conference is organized by industry and is for industry, our board of directors attends, and we address the real and timely issues, and we get the best and most dynamic speakers. 

RB: Who should attend the MedTech conference and why?

RB: Easy – everyone that is a decision maker or will be a decision maker should attend.  This is not just CEOs, but heads of regulatory affairs, executives responsible for payment policy, compliance, legal, market access, business development, investments, etc.

DF: Why should CEOs and investors in particular attend the conference?

RB: This will be the 17^th MedTech Conference. It’s evolved and it gets better every year. Some of the newer features that excite most include two Fireside chats moderated by bank analysts.  Steve MacMillan, CEO of Hologic and Peter Arduini, CEO of GE Healthcare are each delivering one.  A keynote being moderated by Citi’s analyst feature’s Ashely McEvoy, Worldwide chairman of J&J MedTech, Kevin Lobo, Chair and CEO of Stryker and Geoff Martha, Chair and CEO of Medtronic.  I think feature that will most excite the RESI community is our Reverse Pitch series.  Companies delivering these forward-thinking pitches are among the most active in the M&A space and include:. 

• Alcon
• Blackstone Lifesciences
• Boston Scientific
• Edwards Lifesciences
• GE Healthcare
• Haemonetics
• Johnson & Johnson
• Medtronic
• Olympus
• ResMed
• Siemens
• Stryker
• Gore
• ZOLL

Business gets down all day long – from breakfast through the late night.  One event not to be missed will be a fun concert event at The House of Blues featuring Fitz and The Tantrums – this is an internationally acclaimed pop indie band.  There is something for everyone, device, digital health and diagnostic.

DF: I’ve attended nearly every year and frankly find it to be the among the best bargains and wisest uses of time. It is as you described a for-industry-by-industry event. What is the secret to the success of the conference?

RB: The secret sauce – the one time and place to see the entire ecosystem and all stakeholders… Because the AdvaMed Board of Directors, Accel, Dx, Digital Board all meet in conjunction with the conference the leaders of industry are here …

DF: As a long-time partner of LSN and RESI, is there anything special you can offer our community?

RB: Dennis, we do have a great relationship and it dates to the very first RESI conference.  If any of member your community is not already registered and wants to join us for The MedTech Conference in Anaheim this October 8-11, they may register at www.themedtechconference.com and use CODE “LSN25” to receive a discount of 25%.